Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior

Epilepsy and Behavior Case Reports

Volumn 1, Issue 1, 2013, Pages 110-112

  Kaufman, Kenneth R ^a   Bisen, Viwek ^a   Zimmerman, Aphrodite ^a   Tobia, Anthony ^a   Mani, Ram ^a   Wong, Stephen ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Depression; Education; Epilepsy; Impulsive aggressive behavior; Levetiracetam; Psychiatric adverse effect; Suicide attempt; Therapeutic drug monitoring; Traumatic brain injury

Indexed keywords

CREATINE KINASE; ETIRACETAM; LORAZEPAM; OXCARBAZEPINE; PHENYTOIN;

AGED; AGGRESSION; ALCOHOL BLOOD LEVEL; ANEMIA; ARTICLE; BRAIN ATROPHY; BRAIN HEMORRHAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; IMPULSIVENESS; LACUNAR STROKE; MAJOR DEPRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEIZURE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TONIC CLONIC SEIZURE; TRAUMATIC BRAIN INJURY;

EID: 84882770998     PISSN: 22133232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ebcr.2013.07.002     Document Type: Article

References (30)

1. Kaufman K.R. Monotherapy treatment of bipolar disorders with levetiracetam. Epilepsy Behav 2004, 5(6):1017-1020.
2. Lyseng-Williamson K.A. Spotlight on levetiracetam in epilepsy. CNS Drugs 2011, 25(10):901-905.
3. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 2004, 101(26):9861-9866.
4. Kamminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008, 54(4):715-720.
5. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004, 43(11):707-724.
6. Cramer J.A., De Rue K., Devinsky O., Edrich P., Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or anxiety disorder during clinical trials. Epilepsy Behav 2003, 4(2):124-132.
7. Mula M., Trimble M.R., Yuen A., Liu R.S., Sander J.W. Psychiatric adverse events during levetiracetam therapy. Neurology 2003, 61(5):704-706.
8. Helmstaedter C., Fritz N.E., Kockelmann E., Kosanetzky N., Elger C.E. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008, 13(3):525-541.
9. Mazza M., Martini A., Scoppetta M., Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(2):539-543.
10. Cumbo E., Ligori L.D. Levetiracetam, lamotrigine, and phenobarbital in patients with epilepsy and Alzheimer's disease. Epilepsy Behav 2010, 17(4):461-466.
11. Kaufman K.R. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav 2011, 21(1):1-11.
12. Farooq M.U., Bhatt A., Majid A., Gupta R., Khasnis A., Kassab M.Y. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm 2009, 66(6):541-561.
13. Mula M., Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007, 11(1):130-132.
14. Lee J.J., Song H.S., Hwang Y.H., Lee H.W., Suh C.K., Park S.P. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J Clin Neurol 2011, 7(3):128-136.
15. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
16. Patsalos P.N., Berry D.J., Bourgeois B.F., Cloyd J.C., Glauser T.A., Johannessen S.I., et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommittee on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49(7):1239-1276.
17. VanCott A.C., Cramer J.A., Copeland L.A., Zeber J.E., Steinman M.A., Dersh J.J., et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 2010, 8:4.
18. U.S.Food and Drug Administration Statistical review and evaluation: antiepileptic drugs and suicidality [Available at:], [Accessed on May 17, 2013]. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf.
19. Kaufman K.R., Struck P.J. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder. Epilepsy Behav 2011, 20(2):386-389.
20. Mula M., Kanner A.M., Schmitz B., Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychiatry. Epilepsia 2013, 54(1):199-203.
21. Dinkelacker V., Dietl T., Widman G., Lengler U., Elger C.E. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003, 4(5):537-547.
22. Stephen L.J., Kelly K., Parker P., Brodie M.J. Levetiracetam monotherapy - outcome from an epilepsy clinic. Seizure 2011, 20(7):554-557.
23. Mann J.J., Waternaux C., Haas G.L., Malone K.M. Towards a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999, 156(2):181-189.
24. Stoltenberg S.F., Christ C.C., Highland K.B. Serotonin system gene polymorphisms are associated with impulsivity in a context dependent manner. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39(1):182-191.
25. Helmstaedter C., Mihov Y., Toliat M.R., Thiele H., Nuernberg P., Schoch S., et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia 2013, 54(1):36-44.
26. Adelow C., Andersson T., Ahlbom A., Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012, 78(6):396-401.
27. Hesdorffer D.C., Ishihara L., Mynepalli L., Webb D.J., Weil J., Hauser W.A. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012, 72(2):184-191.
28. Wasserman L., Shaw T., Vu M., Ko C., Bollegala D., Bhalerao S. An overview of traumatic brain injury and suicide. Brain Inj 2008, 22(11):811-819.
29. Pompili M., Venturini P., Campi S., Seretti M.E., Montebovi F., Lamis D.A., et al. Do stroke patients have an increased risk of developing suicidal ideation or dying by suicide? An overview of the current literature. CNS Neurosci Ther 2012, 18(9):711-721.
30. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.